To analyze the clinical effect of Qishen Yiqi Dripping Pill (芪参益气滴丸) combined with dapagliflozin and sacubitril-valsartan in the treatment of chronic heart failure.

A total of 206 patients with chronic heart failure with reduced ejection fraction who were admitted to Qinghai Special Hospital of Cardio-cerebrovascular Disease from June 2021 to June 2023 were selected and divided into control group (103 cases) and observation group (103 cases) by random number table method. The control group was treated with dapagliflozin and sacubitril-valsartan, and the observation group was treated with Qishen Yiqi Dripping Pill on the basis of the control group, and both groups were treated continuously for 8 weeks. The TCM syndrome scores, cardiac function index, serological index, 6 min walking test distance, quality of life, clinical efficacy and adverse reactions of the two groups were observed before and after treatment.

After 8 weeks of treatment, the TCM syndrome scores, the levels of left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), hypersensitive C-reactive protein (hs-CRP), amino terminal brain natriuretic peptide precursor (NT-proBNP) and Minnesota Living with Heart Failure Quality of Life Questionnaire (MLHFQ) in the observation group were lower than those of the control group (P<0.05), and the levels of left ventricular ejection fraction (LVEF), cardiac output (CO) and left ventricular ejection fraction (LVEF) and 6 min walking test distance were lower than those of the control group (P<0.05). The total effective rate in the observation group was higher than that of the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).

The combination of Qishen Yiqi Dripping Pill and dapagliflozin and sacubitril-valsartan in the treatment of chronic heart failure can effectively alleviate the clinical symptoms, improve the cardiac function, reduce the inflammatory response and the risk of cardiac remodeling, enhance the cardiac reserve, increase the exercise tolerance and improve the quality of life of the patients, with clear efficacy and high safety.